128 related articles for article (PubMed ID: 20184887)
1. Molecular determinants of Kv1.5 channel block by diphenyl phosphine oxide-1.
Du YM; Zhang XX; Tu DN; Zhao N; Liu YJ; Xiao H; Sanguinetti MC; Zou A; Liao YH
J Mol Cell Cardiol; 2010 Jun; 48(6):1111-20. PubMed ID: 20184887
[TBL] [Abstract][Full Text] [Related]
2. Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation.
Decher N; Kumar P; Gonzalez T; Pirard B; Sanguinetti MC
Mol Pharmacol; 2006 Oct; 70(4):1204-11. PubMed ID: 16835355
[TBL] [Abstract][Full Text] [Related]
3. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
Lagrutta A; Wang J; Fermini B; Salata JJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
[TBL] [Abstract][Full Text] [Related]
4. High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.
Karczewski J; Kiss L; Kane SA; Koblan KS; Lynch RJ; Spencer RH
Biochem Pharmacol; 2009 Jan; 77(2):177-85. PubMed ID: 18955031
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for competition between drug binding and Kvbeta 1.3 accessory subunit-induced N-type inactivation of Kv1.5 channels.
Decher N; Kumar P; Gonzalez T; Renigunta V; Sanguinetti MC
Mol Pharmacol; 2005 Oct; 68(4):995-1005. PubMed ID: 16024663
[TBL] [Abstract][Full Text] [Related]
6. Kvbeta1.3 reduces the degree of stereoselective bupivacaine block of Kv1.5 channels.
Arias C; Guizy M; David M; Marzian S; González T; Decher N; Valenzuela C
Anesthesiology; 2007 Oct; 107(4):641-51. PubMed ID: 17893461
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels.
Decher N; Pirard B; Bundis F; Peukert S; Baringhaus KH; Busch AE; Steinmeyer K; Sanguinetti MC
J Biol Chem; 2004 Jan; 279(1):394-400. PubMed ID: 14578345
[TBL] [Abstract][Full Text] [Related]
8. Quercetin activates human Kv1.5 channels by a residue I502 in the S6 segment.
Yang L; Ma JH; Zhang PH; Zou AR; Tu DN
Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):154-61. PubMed ID: 18986330
[TBL] [Abstract][Full Text] [Related]
9. Cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate and nordihydroguaiaretic acid inhibit human Kv1.5 currents independently of lipoxygenase.
Gong YZ; Ding WG; Wu J; Tsuji K; Horie M; Matsuura H
Eur J Pharmacol; 2008 Dec; 600(1-3):18-25. PubMed ID: 18930721
[TBL] [Abstract][Full Text] [Related]
10. A single residue in the S6 transmembrane domain governs the differential flecainide sensitivity of voltage-gated potassium channels.
Herrera D; Mamarbachi A; Simoes M; Parent L; Sauvé R; Wang Z; Nattel S
Mol Pharmacol; 2005 Aug; 68(2):305-16. PubMed ID: 15883204
[TBL] [Abstract][Full Text] [Related]
11. In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate.
Regan CP; Wallace AA; Cresswell HK; Atkins CL; Lynch JJ
J Pharmacol Exp Ther; 2006 Feb; 316(2):727-32. PubMed ID: 16243963
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes.
Bachmann A; Gutcher I; Kopp K; Brendel J; Bosch RF; Busch AE; Gögelein H
Naunyn Schmiedebergs Arch Pharmacol; 2001 Nov; 364(5):472-8. PubMed ID: 11692231
[TBL] [Abstract][Full Text] [Related]
13. Modeling the binding modes of Kv1.5 potassium channel and blockers.
Yang Q; Du L; Wang X; Li M; You Q
J Mol Graph Model; 2008 Sep; 27(2):178-87. PubMed ID: 18485768
[TBL] [Abstract][Full Text] [Related]
14. Differential sensitivity of voltage-gated potassium channels Kv1.5 and Kv1.2 to acidic pH and molecular identification of pH sensor.
Steidl JV; Yool AJ
Mol Pharmacol; 1999 May; 55(5):812-20. PubMed ID: 10220559
[TBL] [Abstract][Full Text] [Related]
15. Interaction of propofol with voltage-gated human Kv1.5 channel through specific amino acids within the pore region.
Kojima A; Ito Y; Ding WG; Kitagawa H; Matsuura H
Eur J Pharmacol; 2015 Oct; 764():622-632. PubMed ID: 26256861
[TBL] [Abstract][Full Text] [Related]
16. Voltage- and time-dependent block by perhexiline of K+ currents in human atrium and in cells expressing a Kv1.5-type cloned channel.
Rampe D; Wang Z; Fermini B; Wible B; Dage RC; Nattel S
J Pharmacol Exp Ther; 1995 Jul; 274(1):444-9. PubMed ID: 7616429
[TBL] [Abstract][Full Text] [Related]
17. Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications.
Ravens U; Wettwer E
Cardiovasc Res; 2011 Mar; 89(4):776-85. PubMed ID: 21159668
[TBL] [Abstract][Full Text] [Related]
18. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels.
Eldstrom J; Wang Z; Xu H; Pourrier M; Ezrin A; Gibson K; Fedida D
Mol Pharmacol; 2007 Dec; 72(6):1522-34. PubMed ID: 17872968
[TBL] [Abstract][Full Text] [Related]
19. Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea?
Kiper AK; Rinné S; Rolfes C; Ramírez D; Seebohm G; Netter MF; González W; Decher N
Pflugers Arch; 2015 May; 467(5):1081-90. PubMed ID: 25511502
[TBL] [Abstract][Full Text] [Related]
20. State-dependent block of rabbit vascular smooth muscle delayed rectifier and Kv1.5 channels by inhibitors of cytochrome P450-dependent enzymes.
Iftinca M; Waldron GJ; Triggle CR; Cole WC
J Pharmacol Exp Ther; 2001 Aug; 298(2):718-28. PubMed ID: 11454936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
